Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Calcitonin Gene Related Peptide (CGRP) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Calcitonin Gene Related Peptide (CGRP) Products under Development by Stage of Development | 7 | 1 |
| Calcitonin Gene Related Peptide (CGRP) Products under Development by Therapy Area | 8 | 1 |
| Calcitonin Gene Related Peptide (CGRP) Products under Development by Indication | 9 | 1 |
| Calcitonin Gene Related Peptide (CGRP) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Calcitonin Gene Related Peptide (CGRP) Products under Development by Companies | 12 | 2 |
| Calcitonin Gene Related Peptide (CGRP) Therapeutics Assessment | 14 | 6 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 2 |
| Assessment by Molecule Type | 18 | 2 |
| Calcitonin Gene Related Peptide (CGRP) Companies Involved in Therapeutics Development | 20 | 5 |
| Alder Biopharmaceuticals Inc. | 20 | 1 |
| Boehringer Ingelheim GmbH | 21 | 1 |
| Eli Lilly and Company | 22 | 1 |
| Noxxon Pharma AG | 23 | 1 |
| Teva Pharmaceutical Industries Ltd. | 24 | 1 |
| Calcitonin Gene Related Peptide (CGRP) Drug Profiles | 25 | 13 |
| ALD-403 Drug Profile | 25 | 4 |
| galcanezumab Drug Profile | 29 | 2 |
| NOXL-41 Drug Profile | 31 | 1 |
| olcegepant Drug Profile | 32 | 1 |
| Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain Drug Profile | 33 | 1 |
| TEV-48125 Drug Profile | 34 | 4 |
| Calcitonin Gene Related Peptide (CGRP) Dormant Projects | 38 | 2 |
| Calcitonin Gene Related Peptide (CGRP) Discontinued Products | 40 | 1 |
| Calcitonin Gene Related Peptide (CGRP) Featured News &Press Releases | 41 | 15 |
| Sep 08, 2016: Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention | 41 | 1 |
| Sep 06, 2016: Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer | 41 | 1 |
| Jul 25, 2016: Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine | 42 | 1 |
| Jun 09, 2016: Alder Presents Positive Clinical Data for ALD403 at the Annual Meeting of the American Headache Society | 43 | 1 |
| Jun 08, 2016: New drug to prevent migraine may start working in days | 44 | 1 |
| Jun 02, 2016: Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention | 45 | 1 |
| May 25, 2016: Alder BioPharmaceuticals Continues to Strengthen and Expand Leadership Team to Support Advancement of ALD403 for Migraine Prevention | 46 | 1 |
| Apr 12, 2016: Teva to Present Data on TEV-48125 at 68th AAN Annual Meeting | 47 | 1 |
| Mar 28, 2016: Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine | 47 | 2 |
| Feb 09, 2016: Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization | 49 | 1 |
| Oct 13, 2015: Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine | 50 | 1 |
| Sep 30, 2015: Important New Data from Teva's TEV-48125 Phase 2B Migraine Program Published in Lancet Neurology in Back-to-Back Articles | 51 | 1 |
| Jun 18, 2015: Teva to Present New Findings at the American Headache Society Meeting Analysis of Migraine Phase IIb Studies Provides Novel Insights into TEV-48125 Efficacy and Safety in Both Episodic &Chronic Migraine | 52 | 2 |
| Jun 17, 2015: Lilly's investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study | 54 | 1 |
| May 15, 2015: Alder Presents Positive Clinical Data for ALD403 at the 17th Congress of the International Headache Society | 55 | 1 |
| Appendix | 56 | 2 |
| Methodology | 56 | 1 |
| Coverage | 56 | 1 |
| Secondary Research | 56 | 1 |
| Primary Research | 56 | 1 |
| Expert Panel Validation | 56 | 1 |
| Contact Us | 56 | 1 |
| Disclaimer | 57 | 1 |